Healthtech funding in Q3 2020
European Healthtech startup funding raised during Q3 2020.
In Q3 2020, 163 European Healthtech companies closed 164 funding rounds and raised €2.0B in equity funding (excluding debt and grants), up 102.0% versus Q3 2019. Debt rounds added €53M. UK led by capital raised, and Novo Holdings was the most active investor. Data as of 20 Nov 2026.
Equity funding
€2.0B
+102.0% vs Q3 2019 · excl. debt & grants · +€53M debt
Funding rounds
164
+331.6% vs Q3 2019
Companies
163
Top country
UK
Rank among sectors
#5
11.8% of sector funding
Debt financing
€53M
2.6% of total
Top-10 round share
37.1%
of disclosed capital
Rounds ≥ €100M
2
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, Q3 2020 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jul | €858M | 60 |
| Aug | €365M | 40 |
| Sep | €865M | 64 |
Top countries
by € raisedHealthtech — top countries by capital, Q3 2020 — interactive chart.
Data table
| Healthtech — top countries by capital, Q3 2020 | |
|---|---|
| UK | €441M |
| Israel | €416M |
| France | €242M |
| Sweden | €227M |
| Netherlands | €196M |
| Switzerland | €182M |
| Spain | €147M |
| Belgium | €68M |
Stage mix
by € raisedHealthtech — stage mix, Q3 2020 — interactive chart.
Data table
| Healthtech — stage mix, Q3 2020 | |
|---|---|
| Other | €568M |
| Series C | €551M |
| Series B | €315M |
| Series A | €270M |
| Series D+ | €197M |
| Seed | €63M |
| Debt | €53M |
| Early VC | €45M |
| Growth/Late | €17M |
| Pre-Seed | €3.2M |
| Grant | €2.8M |
| Crowdfunding | €2.6M |
Exits & M&A
6 Acquisition · 2 IPO8 exits · €200M disclosed.
| Nanox Imaging | IPO | Aug 2020 | €140M |
| Fiagon | Acquisition | Sep 2020 | €60M |
Top deals
largest disclosed rounds in Q3 2020| Company | Stage | Date | Amount |
|---|---|---|---|
| Kry | Series C | Jul 2020 | €140M |
| Freeline Therapeutics | Series C | Jul 2020 | €107M |
| Neogene Therapeutics | Other | Sep 2020 | €93M |
| Freeline Therapeutics | Series C | Jul 2020 | €71M |
| Lava Therapeutics | Series C | Sep 2020 | €70M |
| Melio | Series C | Sep 2020 | €68M |
| Sight Diagnostics | Series D+ | Jul 2020 | €61M |
| Sight | Series D+ | Aug 2020 | €60M |
| Imcheck Therapeutics | Other | Sep 2020 | €54M |
| F2G | Other | Aug 2020 | €52M |
| WiThings | Series B | Jul 2020 | €51M |
| DNA Script | Series B | Jul 2020 | €46M |
| TytoCare | Early VC | Jul 2020 | €45M |
| Indigo Diabetes | Series B | Jul 2020 | €38M |
| ReViral | Series C | Aug 2020 | €37M |
Top investors
most active in Q3 2020, by deal count- Novo Holdings4 deals
- Bpifrance3 deals
- Invivo Capital Partners3 deals
- 4FO Ventures2 deals
- Adara Ventures2 deals
- Debiopharm Innovation Fund2 deals
- European Innovation Council2 deals
- Eventide Asset Management2 deals
- Heal Capital2 deals
- Mercia Asset Management2 deals